Background and Aims: Preoperative use of vedolizumab has been associated with increased short-term postoperative infectious complications. We assessed this risk in a single-centre cohort of patients with ulcerative colitis undergoing colectomy. 
Introduction
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterized by inflammation of the colonic mucosa causing relapsing episodes of bloody diarrhoea. The introduction of anti-tumour necrosis factor [anti-TNF] agents dramatically impacted the treatment of UC, since they are not only able to induce and maintain [steroid-free] clinical remission, but are also associated with fewer relapses, lower hospitalization and colectomy rates, and increased quality of life. [1] [2] [3] [4] [5] More recently, vedolizumab [Entyvio TM , Takeda Pharmaceuticals], a humanized monoclonal antibody to the α4β7-integrin, also showed efficacy in treatment of moderate-to-severe UC. 6, 7 In an integrated analysis of all pivotal trials with vedolizumab, its long-term safety was evaluated. 8 In this cohort of 2830 patients with 4811 person-years of vedolizumab exposure, no increased risk of [serious] infections was reported. Although vedolizumab can probably be regarded safer than anti-TNF therapy based on its gutselective mode of action, data on surgical outcomes only recently became available. In a sub-analysis of the GEMINI 1 dataset, postoperative complications were reported in, respectively, 13.3% [2/15] and 33.3% [1/3] of patients who preoperatively had been treated with vedolizumab or placebo. 9 Recent data from the Mayo Clinic [Rochester, MN, USA] suggested increased short-term infectious complications in patients with Crohn's disease or UC undergoing abdominal surgery within 12 weeks of vedolizumab. 10 Within 30 days of surgery, patients in the vedolizumab group more often had surgical site infections compared to patients in the anti-TNF and no biological group [37% vs 10% vs 6%, respectively, p < 0.01] and postoperative infections overall [53% vs 28% vs 33%, respectively, p < 0.01]. In multivariate analysis, use of vedolizumab within 12 weeks of surgery was the only independent predictor of surgical site infections. Although many methodological issues could be raised, it remains crucial for both patients and physicians to understand potential risks of biological therapies in patients who might need to undergo colectomy.
We assessed the risk of perioperative use of vedolizumab in development of short-term postoperative complications in patients with UC undergoing a colectomy.
Materials and methods

Patient population
Through a prospectively maintained surgical database, we identified all patients with UC undergoing a colectomy at the University Hospitals of Leuven [Leuven, Belgium] . The 10-year selection period ran from September 2006 [initiation of vedolizumab studies in our referral centre] to September 2016. Diagnosis of UC was confirmed after review of medical and pathological records. 11, 12 Exclusion criteria were the anticipated construction of a permanent ileostomy and the preoperative use of other investigational products than vedolizumab within 16 weeks of first stage of surgery.
Clinical charts of all patients were reviewed to trace sex, age at diagnosis, age and disease duration at first stage of surgery, presence of primary sclerosing cholangitis, smoking behaviour, familial history of IBD, extent of disease prior to colectomy, body weight, body mass index [BMI] Over the study period, surgery was performed by three experienced abdominal surgeons [AD, AdBvO, AW]. The decision to perform a total colectomy with ileostomy was based on the clinical appreciation of the severity of disease. Follow-up data were obtained by standardized and regular outpatient visits which included detailed history, clinical examination and further imaging if indicated.
Preoperative medical therapy
Based on their half-lives, preoperative use of vedolizumab was defined as a last infusion within 16 weeks, and preoperative use of anti-TNF as a last administration of anti-TNF within 8 weeks of first stage of surgery. 13 Preoperative corticosteroid use was divided into three groups: high dose [intravenous or oral methylprednisolone ≥40 mg/day], moderate dose [oral ≥20 mg/day for more than 2 months] and low-dose [oral < 20 mg/day or oral ≥20 mg/day for less than 2 months].
14 Patients who had stopped methylprednisolone prior to colectomy were not classified in the steroids group, regardless of the duration between last administration and colectomy. Based on previous observations we looked specifically at the subgroup of patients using a moderate-to-high dose of steroids. 15 Patients who did not receive one of the aforementioned medical therapies were defined as 'other therapy group'. This group included patients on mesalamine, topical steroids, a low dose of systemic steroids, thiopurines, methotrexate, calcineurin inhibitors, antibiotics or no therapy.
To facilitate comparison with the data published by Lightner et al., we also performed a separate analysis for patients who had received vedolizumab, infliximab or no biological therapy within 12 weeks of surgery. 10 
Short-term postoperative complications
Short-term postoperative complications were recorded within the first 30 days after first stage of surgery. Infectious complications were divided into pouch-specific, surgical site and nonsurgical site infectious complications. Pouch-specific complications included anastomotic leaks with or without need for antibiotics or re-laparotomy, 16 while surgical site infections included superficial and deep wound infections. 17 Nonsurgical site infections included gastroenteritis, respiratory tract infections, urinary tract infections, catheter sepsis, fever of unknown origin, oral candidiasis, oral aphthous ulcers, toxic exanthema and spondylodiscitis. Short-term noninfectious complications included prolonged ileus, [sub]obstruction, anaemia with or without need for transfusion, dehydration, venous thrombosis, urinary retention, pneumothorax, compression neuropathy, liver decompensation and arrhythmias.
Each short-term postoperative complication was classified according to Clavien-Dindo criteria. 18 Furthermore, the comprehensive complication index [CCI] was calculated based on all complications reported within 30 days of first stage of surgery. 19 The recently developed CCI is based on the Clavien-Dindo classification for postoperative morbidity and is calculated using a predefined formula, resulting in a number between 0 and 100. This number reflects severity of complications and has the advantage to include all occurring complications in contrast to the 'classical' Clavien-Dindo classification, which only takes the most severe complication into account, omitting all concurrent morbidity. A Clavien- Dindo 
Statistical analysis
Chi-square, Fisher exact, Mann-Whitney and backward Wald multiple binary logistic regression were performed using the IBM SPSS Statistics 23.0 software package. Besides some predefined variables [perioperative use of vedolizumab, anti-TNF or a moderate-to-high dose of steroids], variables associated with postoperative complications in univariate analysis were first assessed for collinearity and examined in multivariate analysis thereafter to define independent contributions of each of these factors. The threshold for statistical significance was predefined at p < 0.05.
Results
Study population
Overall, 192 patients with UC underwent acolectomy. Eight patients were excluded because they underwent proctocolectomy with permanent ileostomy [ Figure 1 ]. Fourteen patients were excluded because they participated in a clinical trial and may have received another 
Preoperative medical therapy
As shown in Figure 2 and Supplementary Table S1, 32 
Surgical characteristics
By September 2016, 160 out of 170 patients had completed all surgical stages with construction of an IPAA and restoration of the faecal stream [ Table 1 ]. In four patients the final surgical procedure was planned after September 2016. In another three patients the final procedure was postponed due to postoperative complications [n = 2] or diagnosis of a lymphoma in the resection specimen [n = 1]. Finally, in three patients the IPAA had not yet been constructed on a specific patient's request.
In 
Predictors of short-term postoperative complications
As shown in Figure 3 and Supplementary Table S4 , none of the preoperative medical therapies of interest was associated with an Table 2 , the only variable independently associated with short-term postoperative [infectious or noninfectious] complications was the construction of the pouch at first stage of surgery.
The 30 day CCI and postoperative hospital stay were influenced only by construction of the pouch at first stage of surgery and not by anti-TNF or moderate-to-high dose of steroids [ Figure 4 ]. Patients who had received vedolizumab tended to have a lower CCI and had a significantly lower postoperative hospitalization stay. Similarly, readmission rates were significantly lower in patients who had received vedolizumab (3% vs 21%, odds ratio 0.12 [0.02-0.89], p = 0.011).
Also, if we looked at the subpopulations of patients in whom the pouch was constructed at first or second stage, preoperative use of vedolizumab was not associated with short-term postoperative complications [Supplementary Figure S3 and Table S5 ]. In patients in whom the pouch was constructed at a second stage of surgery, a haemoglobin below 10 mg/dl was the only factor independently associated with short-term infectious complications [Supplementary Table  S6 ]. For short-term noninfectious complications and complications overall in this subpopulation, no independent predictor could be determined. Both CCI and hospitalization stay were not negatively influenced by perioperative therapy [data not shown]. However, patients with a haemoglobin below 10 mg/dl had a higher shortterm CCI (20. Finally, we also performed a similar analysis as in the original paper by the Mayo clinic. As shown in Figure 5 , neither preoperative vedolizumab nor preoperative anti-TNF therapy was associated with short-term postoperative [infectious or noninfectious] complications.
Discussion
We performed a cohort study of all 170 patients with UC undergoing a colectomy over a 10-year period looking at postoperative 
80%
Anastomotic leakage complications. Based on a recent alarming article by Lightner et al., 10 we aimed to evaluate the effect of perioperative vedolizumab on the occurrence of both short-term postoperative infectious and noninfectious complications. Furthermore, we compared outcome with that of patients who received anti-TNF therapy, a moderate-to-high dose of steroids or other therapy. In contrast to the recent findings of the Mayo Clinic, we were not able to demonstrate a higher risk of postoperative infectious complications in patients who had received vedolizumab within 16 weeks of first stage of surgery. Furthermore, none of the medical therapies of interest was associated with shortterm postoperative [infectious] complications. The only independent risk factor for short-term postoperative infectious and noninfectious complications was pouch construction at first stage of surgery. Also, in the subpopulation of patients in whom the pouch was only constructed at a second stage, vedolizumab was not associated with short-term complications after colectomy. However, in this subpopulation, perioperative anaemia was associated with short-term postoperative infectious complications, a higher CCI and a longer postoperative hospitalization stay. Although many authors reported no increased safety risk with vedolizumab, short-term postoperative [infectious] complications were mostly not addressed. 8, [20] [21] [22] [23] The recent results highlighted in the paper by the Mayo Clinic reflected the surgeons' concern about blocking leucocyte migration to the intestine in the perioperative setting. 10 Indeed, leucocytes are a major component of wound healing and failure of appropriate intestinal healing may contribute to anastomotic leaks and organ space surgical site infections. However, vedolizumab mainly blocks lymphocyte trafficking, while mainly neutrophils and macrophages play an important role in wound healing. 24 These leucocyte subsets are probably not affected by an anti-α4β7-integrin antibody.
Pouch-related infectious complications
Short-term postoperative complications
As for all retrospective studies, it is unclear if the different patient populations in the study by Lightner et al. were comparable. 10 Patients in the vedolizumab group were probably more refractory, not only reflected by the numerically higher CRP and the numerically higher use of concomitant steroids and concomitant immunomodulatory drugs, but also by the fact that most of these patients had already experienced [and failed] therapy with steroids and anti-TNF therapy. As it is well known that patients with a more severe disease are more at risk for infectious [serious] adverse events, 25, 26 it is unclear if the observed association with perioperative use of vedolizumab proves causality.
In the study by the Mayo Clinic, the cut-off value for preoperative exposure to vedolizumab and anti-TNF therapy was exactly the same, namely 12 weeks. 10 We decided to categorize the eligible patients differently and based these categories on the clearly different half-life of the biologicals, being 10-14 days for anti-TNF and 25 days for vedolizumab. 13 We also repeated our analysis using the criteria proposed by Lightner et al., but this did not influence our results.
Meanwhile, two other centres evaluated the risk of vedolizumab in the perioperative setting. Stringfield et al. reported their experience in 26 IBD patients who underwent intra-abdominal or anorectal surgeries while treated with vedolizumab. 27 The overall rate of infectious complications was 44% with an anastomotic leak rate of 15%. The authors did not observe significant differences in the number of vedolizumab doses, time of surgery since last dose of vedolizumab or number of failed biologic therapies prior to vedolizumab between those with and without postoperative complications. Koh et al. reported their experience in 15 patients with IBD who had failed vedolizumab and required surgery. 28 Only two patients had a short-term postoperative complication [one wound abscess and one readmission for ileus]. The authors concluded that vedolizumab had a promising safety profile for patients on salvage therapy prior to surgery.
The only independent risk factor for short-term postoperative [infectious and noninfectious] complications in our cohort was the development of the pouch at first stage of surgery. If there is indeed an increased risk linked to preoperative use of vedolizumab, anti-TNF therapy and moderate-to-high doses of corticosteroids, this risk might be overcome by maintaining a more conservative surgical approach and postponing pouch construction to a second stage. Also, in the subpopulation of patients in whom pouch construction was postponed, perioperative medical therapy was not associated with short-term postoperative [infectious or noninfectious] complications. After our previous cohort study, pouch surgery is indeed mostly postponed to a second stage in patients under immunosuppressive therapy. 15 Other authors have also described lower shortterm postoperative infectious complications if pouch construction is postponed. In the subpopulation of patients in whom the pouch construction was postponed to a second stage of surgery, the only variable independently associated with short-term postoperative infectious complications was perioperative anaemia [haemoglobin below 10 g/ dl]. Furthermore, anaemia was also associated with a higher CCI and a longer postoperative hospitalization stay. Perioperative anaemia is a well-known risk factor for postoperative complications, 31 and in this specific situation may be a surrogate marker for severe disease.
Our cohort study has some limitations. First, as for all similar retrospective studies, the sample size was too small to draw any strong conclusions. Furthermore, as for most retrospective studies, we were lacking a good assessment of preoperative disease activity, such as Mayo score or Truelove-Witts index. 32 We only had indirect evidence of increased disease activity, measured by CRP, serum albumin, haemoglobin and concomitant therapies. All these indirect factors of disease severity were associated with a more frequent construction of the pouch in a second stage, but not with an increased risk of postoperative complications. Similarly, we lacked data on serum levels of biological therapies at colectomy. A previous study has suggested increased postoperative complications in patients with higher preoperative anti-TNF serum levels. 33 Next, the inclusion period of 10 years may be associated with different surgical techniques and experience, potentially causing a bias.
We also must consider that our study may be underpowered to detect a difference in short-term postoperative infectious complications. Although our sample size is larger than those in previously published trials, we certainly need large multicentre studies to conclude on the exact detrimental role of preoperative therapy. Such trials should ideally be prospective and take into account all confounding factors, such as disease severity and type of surgery.
In conclusion, in this large retrospective analysis evaluating patients with UC undergoing colectomy, we did not observe an increased risk of postoperative [infectious or noninfectious] complications in patients who recently received vedolizumab. However, a more conservative approach, with pouch construction only at a second stage, seems advisable in patients under biological therapy.
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